Storia in 4 fonti

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.

Raccontata da

morningstar.com

biopharmadive.com

benzinga.com

economictimes.indiatimes.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo23 h fa

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Capricor shares surged 67.22% after-hours: Q2 miss ($0.70 loss vs $0.58 estimate), zero revenue, $237.9M cash. Deramiocel BLA in FDA active review. Extreme oversold (RSI 16.47, down 45.89% YTD) signals speculative recovery play on regulatory catalyst.

originale

Timeline cronologica

mercoledì 12 agosto 2026·morningstar.com
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed,…
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
venerdì 14 agosto 2026·biopharmadive.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the…

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Confronto fonti

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Timeline cronologica

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed,…

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities…

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes